Aurobindo Pharma gets nod for promotion of manufacturing critical bulk drugs

23 Jan 2021 Evaluate

The government has given approval to Aurobindo Pharma under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country.

The Ministry of Chemicals and Fertilizers said the applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production of Penicillin G, and 7-ACA, with committed production capacity of15,000 MT and 2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA is Rs 813 crore.

The approval has also been given to Aurobindo Pharma (through Qule Pharma) for setting up plant for production of Erythromycin Thiocyanate (TIOC), with committed production capacity of1,600 MT at a committed investment of Rs 834 crore.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1089.45 19.45 (1.82%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.